NCT05700656 2024-07-22
Galunisertib Combined With Capecitabine in Advanced CRC With PM
The Netherlands Cancer Institute
Phase 1/2 Recruiting
Clinical Trials
4 trialsNCT02423343 2021-09-09
A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma
Eli Lilly and Company
Phase 1/2 Completed
NCT03470350 2019-07-24
EORTC1615
The Netherlands Cancer Institute
Phase 1/2 Withdrawn
NCT01373164 2018-05-16
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Eli Lilly and Company
Phase 1/2 Completed